91 related articles for article (PubMed ID: 25007399)
1. [111In-DOTA]LTT-SS28, a first pansomatostatin radioligand for in vivo targeting of somatostatin receptor-positive tumors.
Maina T; Cescato R; Waser B; Tatsi A; Kaloudi A; Krenning EP; de Jong M; Nock BA; Reubi JC
J Med Chem; 2014 Aug; 57(15):6564-71. PubMed ID: 25007399
[TBL] [Abstract][Full Text] [Related]
2. [111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study.
Tatsi A; Maina T; Cescato R; Waser B; Krenning EP; de Jong M; Cordopatis P; Reubi JC; Nock BA
EJNMMI Res; 2012 Jun; 2(1):25. PubMed ID: 22682002
[TBL] [Abstract][Full Text] [Related]
3. Fish somatostatin sst3 receptor: comparison of radioligand and GTPgammaS binding, adenylate cyclase and phospholipase C activities reveals different agonist-dependent pharmacological signatures.
Siehler S; Nunn C; Zupanc GK; Hoyer D
Auton Autacoid Pharmacol; 2005 Jan; 25(1):1-16. PubMed ID: 15659149
[TBL] [Abstract][Full Text] [Related]
4. New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting.
Ginj M; Zhang H; Eisenwiener KP; Wild D; Schulz S; Rink H; Cescato R; Reubi JC; Maecke HR
Clin Cancer Res; 2008 Apr; 14(7):2019-27. PubMed ID: 18381940
[TBL] [Abstract][Full Text] [Related]
5. Characterisation of human recombinant somatostatin receptors. 4. Modulation of phospholipase C activity.
Siehler S; Hoyer D
Naunyn Schmiedebergs Arch Pharmacol; 1999 Nov; 360(5):522-32. PubMed ID: 10598791
[TBL] [Abstract][Full Text] [Related]
6. [DOTA]Somatostatin-14 analogs and their (111)In-radioligands: effects of decreasing ring-size on sst1-5 profile, stability and tumor targeting.
Tatsi A; Maina T; Cescato R; Waser B; Krenning EP; de Jong M; Cordopatis P; Reubi JC; Nock BA
Eur J Med Chem; 2014 Feb; 73():30-7. PubMed ID: 24378707
[TBL] [Abstract][Full Text] [Related]
7. Characterisation of the fish sst3 receptor, a member of the SRIF1 receptor family: atypical pharmacological features.
Siehler S; Zupanc GK; Seuwen K; Hoyer D
Neuropharmacology; 1999 Mar; 38(3):449-62. PubMed ID: 10219983
[TBL] [Abstract][Full Text] [Related]
8. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
Wild D; Schmitt JS; Ginj M; Mäcke HR; Bernard BF; Krenning E; De Jong M; Wenger S; Reubi JC
Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1338-47. PubMed ID: 12937948
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of human recombinant somatostatin receptors. 2. Modulation of GTPgammaS binding.
Siehler S; Hoyer D
Naunyn Schmiedebergs Arch Pharmacol; 1999 Nov; 360(5):500-9. PubMed ID: 10598789
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies.
Cyr JE; Pearson DA; Wilson DM; Nelson CA; Guaraldi M; Azure MT; Lister-James J; Dinkelborg LM; Dean RT
J Med Chem; 2007 Mar; 50(6):1354-64. PubMed ID: 17315859
[TBL] [Abstract][Full Text] [Related]
11. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.
Cescato R; Schulz S; Waser B; Eltschinger V; Rivier JE; Wester HJ; Culler M; Ginj M; Liu Q; Schonbrunn A; Reubi JC
J Nucl Med; 2006 Mar; 47(3):502-11. PubMed ID: 16513620
[TBL] [Abstract][Full Text] [Related]
12. Influence of different spacers on the biological profile of a DOTA-somatostatin analogue.
Antunes P; Ginj M; Walter MA; Chen J; Reubi JC; Maecke HR
Bioconjug Chem; 2007; 18(1):84-92. PubMed ID: 17226960
[TBL] [Abstract][Full Text] [Related]
13. [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
Siehler S; Seuwen K; Hoyer D
Eur J Pharmacol; 1998 May; 348(2-3):311-20. PubMed ID: 9652348
[TBL] [Abstract][Full Text] [Related]
14. Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
Siehler S; Seuwen K; Hoyer D
Naunyn Schmiedebergs Arch Pharmacol; 1999 Nov; 360(5):488-99. PubMed ID: 10598788
[TBL] [Abstract][Full Text] [Related]
15. Stabilized (111)in-labeled sCCK8 analogues for targeting CCK2-receptor positive tumors: synthesis and evaluation.
Roosenburg S; Laverman P; Joosten L; Eek A; Oyen WJ; de Jong M; Rutjes FP; van Delft FL; Boerman OC
Bioconjug Chem; 2010 Apr; 21(4):663-70. PubMed ID: 20302291
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy.
Wang X; Fani M; Schulz S; Rivier J; Reubi JC; Maecke HR
Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1876-85. PubMed ID: 22926735
[TBL] [Abstract][Full Text] [Related]
17. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy.
Smith-Jones PM; Bischof C; Leimer M; Gludovacz D; Angelberger P; Pangerl T; Peck-Radosavljevic M; Hamilton G; Kaserer K; Kofler A; Schlangbauer-Wadl H; Traub T; Virgolini I
Endocrinology; 1999 Nov; 140(11):5136-48. PubMed ID: 10537142
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo comparison of human Escherichia coli heat-stable peptide analogues incorporating the 111In-DOTA group and distinct linker moieties.
Giblin MF; Gali H; Sieckman GL; Owen NK; Hoffman TJ; Forte LR; Volkert WA
Bioconjug Chem; 2004; 15(4):872-80. PubMed ID: 15264876
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 111In-DOTA-NOC and 111I-DOTA-TATE distribution in the target and dose-limiting tissues: conflicting results in vitro and in vivo.
Cihlo J; Melicharová L; Petrik M; Laznickova A; Laznicek M
Anticancer Res; 2008; 28(4B):2189-95. PubMed ID: 18751394
[TBL] [Abstract][Full Text] [Related]
20. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
